

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ABX-PF/1

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Amgen Fremont Inc.

Patent No.: 6,682,736 Issue Date: 01-27-2004; Conf No. 8298

Entitled: HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

Amgen Fremont Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- ☐ the assignee of the entire right, title, and interest; or
- ☒ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is 50%)

in the patent application/patent identified above by virtue of either:

☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel/Frame _____, or for which a copy thereof is attached.

OR

☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

- C. Geoffrey Davis and
1. From: Jose Ramon Corvalan To: Abgenix, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 012709, Frame 0559, or for which a copy thereof is attached.
- C. Geoffrey Davis and
2. From: Jose Ramon Corvalan To: Abgenix, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 012709, Frame 0570, or for which a copy thereof is attached.
3. From: Abgenix, Inc. To: Amgen Fremont Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 022575, Frame 0476, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Stuart L. Watt

Signature
Stuart L. Watt

Printed or Typed Name

Vice President, Law and Intellectual Property Officer

Title

July 22, 2009

Date
805-447-1000

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on this version of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No. ABX-PF11

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Pfizer Inc.

Patent No.: 6,682,736

Issue Date: 01-27-2004; Conf No. 8298

Entitled: HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

Pfizer Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or

2. ☒ an assignee of less than the entire right, title and interest
(The extent of ownership is an undivided interest between two parties -- Pfizer Inc. and Abgenix, Inc.)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel/Frame 012709/0566, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____


The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature
Gregg C. Benson

Assistant General Counsel

Title

18 June 2009

Date
860-441-4901

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormWorkflow.com